Picture of AstraZeneca logo

AZN — AstraZeneca News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

AstraZeneca Q3 revenue rises 7% on Oncology unit strength

AstraZeneca Q3 revenue rises 7% on Oncology unit strength


Overview

  • UK pharma group's Q3 revenue rose 7% yr/yr, beating analyst expectations

  • Core EPS for Q3 increased 17% and beat analyst expectations

  • Growth in Oncology, R&I and Rare Disease offset declines in some cardiovascular drugs


Outlook

  • AstraZeneca expects FY 2026 total revenue to rise by a mid-to-high single-digit percentage

  • Company forecasts FY 2026 core EPS to grow by a low double-digit percentage

  • AstraZeneca anticipates FY 2026 core tax rate between 18% and 22%


Result Drivers

  • ONCOLOGY, R&I, RARE DISEASE GROWTH - Co said double-digit growth in Oncology, Respiratory & Immunology, and Rare Disease segments offset declines in some cardiovascular drugs

  • PRODUCT MIX, PRICING PRESSURE - Gross margin benefited from positive product mix, but was partly offset by pricing headwinds and loss of exclusivity, especially in China

  • GENERIC COMPETITION - Loss of exclusivity and generic competition weighed on Farxiga and Brilinta sales


Company press release: ID:nRSd0827Ba


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$16.21 bln

$16.03 bln (16 Analysts)

Q3 Core EPS

Beat

$2.79

$2.59 (15 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for AstraZeneca PLC is GBp16,000.00, about 22.6% above its October 29 closing price of GBp13,052.00

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago


Reuters Recommended Reads

  • Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat

  • Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand

  • Oct 29 - Merck Q3 profit beats on Keytruda demand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AstraZeneca

See all news